Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

IMMUNOGEN, INC. (IMGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

ImmunoGen, Inc. : Initiates Phase I Trial in Non-Hodgkin's Lymphoma with Its Novel IMGN529 Anticancer Compound

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2012 | 12:20pm CEST

- First of Two Unique ImmunoGen Product Candidates Expected to Enter Clinic in 2012 -

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate. The Phase I trial initiated evaluates the safety, tolerability, pharmacokinetic profile and anticancer activity of escalating doses of IMGN529 in patients with non-Hodgkin's lymphoma (NHL) to establish the dose for future clinical trials.

Today NHL is frequently treated with the anticancer antibody, rituximab (Rituxan®), and/or with chemotherapy. The novel agent IMGN529, a TAP compound, contains a B-cell-targeting antibody that has demonstrated marked anticancer activity in preclinical testing.1 Attached to this antibody is a potent ImmunoGen cell-killing agent, DM1. The antibody serves: (1) to kill the cancer cells through multiple antibody-mediated mechanisms; and (2) to deliver the DM1 specifically to the cancer cells for additional, targeted anticancer potency.

"The Phase I trial now underway, together with our market research, is expected to provide the information needed to define a clear development path for IMGN529 in NHL," commented James O'Leary, MD, Vice President and Chief Medical Officer. "With its unique profile, we believe IMGN529 has the potential to be an important new therapy for the treatment of key B-cell malignancies."

About the Phase I Trial Initiated

This multi-center, first-in-human Phase I trial is expected to enroll approximately 55 patients with relapsed or relapsed/refractory, CD37-expressing NHL. Patients with follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, or marginal zone lymphoma - the more common types of NHL - are eligible for enrollment.

About IMGN529

ImmunoGen created IMGN529 for the treatment of B-cell malignancies that express its CD37 target. The prevalence of CD37 on malignant cells is similar to that of CD20, the target for rituximab: it is expressed widely on key NHL subtypes - including follicular lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma and mantle cell lymphoma - and also on chronic lymphocytic leukemia (CLL).1

IMGN529 contains a CD37-targeting ImmunoGen antibody that, in vitro, has been found to kill cancer cells through multiple mechanisms of action including pro-apoptotic activity, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).1,2 The attached DM1 kills cancer cells through a different mechanism - disruption of a key step that occurs during cell division.

About Non-Hodgkin's lymphoma

NHL comprises a diverse group of cancers that all derive from defects in cellular production of lymphocytes, a type of white blood cell. As the name suggests, NHL includes all lymphomas except Hodgkin's lymphoma. Approximately 85% of cases of NHL are B-cell lymphomas. It is estimated that, in the US, approximately 56,000 people are diagnosed with B-cell NHL each year and 16,000 die from the disease.3

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development with a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare, Biotest, Lilly, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.

1Mayo M. et al., AACR 2011, abstract #4581.
2Deckert J. et al., AACR 2011, abstract #4565.
3American Cancer Society, What is non-Hodgkin's Lymphoma.

Rituxan® is a registered trademark of Biogen Idec Inc.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including IMGN529, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2011 and other reports filed with the Securities and Exchange Commission.

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
[email protected]
or
For Media:
The Yates Network
Kathryn Morris, 845-635-9828


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOGEN, INC.
01:33pFree Technical Research on ImmunoGen and Three More Biotech Equities
AC
06/21IMMUNOGEN : Investigators at ImmunoGen, Inc. Discuss Findings in Acute Myeloid L..
AQ
06/21IMMUNOGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/21IMMUNOGEN : Announces Full Exercise of Underwriters’ Option to Purchase Ad..
BU
06/18IMMUNOGEN : Announces FDA Fast Track Designation for Mirvetuximab Soravtansine i..
BU
06/13IMMUNOGEN : Announces Closing of Public Offering of Common Stock
AQ
06/11IMMUNOGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/11IMMUNOGEN : Announces Closing of Public Offering of Common Stock
BU
06/07IMMUNOGEN INC : Entry into a Material Definitive Agreement, Other Events, Financ..
AQ
06/07FOLLOW-ON ROUNDUP : ImmunoGen, Mirati, Zymeworks, OptiNose
AQ
More news
News from SeekingAlpha
06/20YOUR DAILY PHARMA SCOOP : TG Therapeutics Phase 2 Results, Geron Positive, Agio .. 
06/18ImmunoGen's mirvetuximab soravtansine Fast Track'd for treatment-resistant ov.. 
06/18PREMARKET GAINERS AS OF 9 : 05 am (06/18/2018) 
06/16A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals 
06/14IMMUNOGEN : Secondary Offers Ideal Entry Point 
Financials ($)
Sales 2018 64,1 M
EBIT 2018 -140 M
Net income 2018 -151 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 25,7x
EV / Sales 2019 18,5x
Capitalization 1 645 M
Chart IMMUNOGEN, INC.
Duration : Period :
ImmunoGen, Inc. Technical Analysis Chart | IMGN | US45253H1014 | 4-Traders
Technical analysis trends IMMUNOGEN, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 12,0 $
Spread / Average Target 2,7%
EPS Revisions
Managers
NameTitle
Mark J. Enyedy President, Chief Executive Officer & Director
Stephen C. McCluski Chairman
David B. Johnston Chief Financial Officer & Executive Vice President
Richard J. Gregory Chief Scientific Officer & Executive VP
Anna Berkenblit Chief Medical Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOGEN, INC.74.88%1 645
CELLTRION, INC.--.--%33 064
IQVIA HOLDINGS INC6.98%21 789
LONZA GROUP2.35%20 356
INCYTE CORPORATION-22.94%15 565
ALNYLAM PHARMACEUTICALS, INC.-17.65%10 581